Sagopilone

Drug Profile

Sagopilone

Alternative Names: BAY86-5302; SH Y03757A; SHY-03757; ZK 219477; ZK epothilone; ZK-EPO

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 18 Dec 2009 Interim adverse events and pharmacokinetics data from a phase I trial in solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top